FORE Biotherapeutics Names William R. Hinshaw as Chief Executive Officer
FORE Biotherapeutics to Participate in Upcoming Investor Conferences
FORE Biotherapeutics to Present at the 2023 RBC Capital Markets Private Company Conference
FORE Biotherapeutics Announces Oral Presentation of Phase 1/2a Plixorafenib Data
FORE Biotherapeutics to Present Plixorafenib Nonclinical Data Highlighting Potential Differentiation at the 2023 AACR-NCI-EORTC International Conference
FORE Biotherapeutics Announces $75M in Series D Financing and CEO Transition
PHILADELPHIA--(BUSINESS WIRE)--FORE Biotherapeutics today announced new clinical data from the Phase 1/2a clinical trial for plixorafenib (FORE8394), a novel, investigational, small-molecule, next-generation, orally available selective inhibitor of BRAF alterations. The results demonstrate promising single-agent activity against BRAF-altered tumors, including primary central nervous system (CNS) tumors, and will be featured in presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 2-6, 2023, in Chicago, IL.
PHILADELPHIA--(BUSINESS WIRE)--FORE Biotherapeutics today announced the acceptance of two abstracts on new clinical data related to FORE8394, the company's novel, investigational, small-molecule, next-generation, orally available selective inhibitor of BRAF alterations at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7, 2023, in Chicago and virtually. The datasets from the phase 1/2a clinical trial, evaluating the safety, tolerability, and efficacy of FORE8394 as a monotherapy will be presented.
FORE Biotherapeutics Receives FDA Orphan Drug Designation for FORE8394 for the Treatment of Primary Brain and CNS Malignancies
Fore Biotherapeutics Announces First Patient Dosed in Global Phase 2 Trial Evaluating FORE8394 in BRAF-Mutated Solid and Brain Tumors